Investors 

Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris

 

Press Releases

20/07/2016

 

Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic

 

>  Internationalization of the HPV clinical trial with the participation of two reputed Czech hospitals

>  The first patients are currently being enrolled

>  Interim results are expected in early 2017

 

 

Bagneux (France) – Genomic Vision (FR0011799907 – GV), DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, today announces the first enrollments in the clinical trial being organized in the Czech Republic aimed at validating the integration of the oncogenic, i.e. high-risk, human papillomavirus (HPV-HR) as an indicator of the severity of cervical lesions.

 

This trial is being undertaken in two major hospitals, the Brno Centre for Outpatient Gynaecology and Primary Care (Dr. Vladimír Dvořák) and the Brno University Hospital (Prof. Pavel Ventruba), and foresees the inclusion of 993 female patients. The primary end-point of this study is to prove that the integration of HPV is a biomarker for diagnosing high-risk precancerous lesions that require appropriate treatment to be defined. The initial results of this pilot study are expected in early 2017.

 

Aaron Bensimon, Genomic Vision’s co-founder and Chairman, comments:We wanted to launch this study simultaneously with the IDAHO trial, currently being undertaken with Reims University Hospital and other French medical centers, in order to accelerate and internationalize our HPV test development program. Indeed, following feedback from clinicians, it is clear that there is a real need for more specific diagnostic tests capable of detecting high-grade precancerous lesions that are likely to evolve into cancerous lesions in the cervix. Thanks to a high enrollment pace, the initial results of this study will be available by the beginning of 2017.

 

The integration of HPV DNA in a host’s genome is considered to be a key event in the progression of precancerous lesions into cancerous lesions in the cervix. The aim of this study is to determine whether the integration of HPV-HR DNA in patients’ genomes is a sufficient indicator of diagnostics, i.e. of the severity of lesions. Genomic Vision’s molecular combing technique is currently the only one that allows the frequency of the integration of high-risk HPV-HR to be detected, in a direct and high resolution manner.

 

Dr. Dvořák, Head Physician at the Brno Centre for Outpatient Gynaecology and Primary Care, and principal investigator for the study, adds:HPV infection, which is in some cases related to cervical cancer, is one of main threats to women´s health. Every improvement in diagnostics is very important, as it can influence the treatment program for each individual patient. For these reasons, I have agreed to participate in the HPV trial organized by Genomic Vision. Should its positive results be confirmed, physicians will have access to a new tool enabling them to more accurately predict the severity of HPV infection with regard to the development of cervical cancer.”

 

 


Upcoming financial publication

2016 half-year results, Tuesday, July 26, 2016 (after trading)

 

 


CONTACTS

Genomic Vision: Aaron Bensimon Co-founder, Chairman & CEO Tel.: +33 1 49 08 07 50 investisseurs@genomicvision.com

 

Kalima Relations Presse / Estelle Reine-Adélaïde / Florence Calba/Tel.: +33 6 17 72 74 73 / +33 1 44 90 82 54  era@kalima-rp.fr

 

NewCap Investor Relations / Strategic Communications Dušan Orešanský / Emmanuel Huynh Tel.: +33 1 44 71 94 92 gv@newcap.eu

 

LHA: Investor Relations US: Anne Marie Fields, SVP Tel.: 212-838-3777 afields@lhai.com 

 

Member of CAC® Mid & Small, CAC® All-Tradable and EnterNext© PEA-PME 150 indexes

 

frise

genomic_web_visuels_footer_COMPANY